GleamWall
中文EN

REGN REGENERON PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 872589 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.6%
TTM net income YoY5.2%
TTM EPS YoY8.4%
Revenue 3-yr CAGR8.9%
Net income 3-yr CAGR6.5%

Margins

Gross margin—
Operating margin28.8%
Net margin28.5%
FCF margin22.6%
EBITDA margin31.8%

Returns

ROE14.9%
ROA11.4%
ROIC (approx.)13.2%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets24.6%
Debt / equity0.06x
Current ratio3.35x
Interest coverage104.16x

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio-0.1%
Payout ratio8.0%
Capex / revenue6.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$5.12B$4.29B$3.61B$3.88B$3.75B$3.68B$3.03B$3.79B
R&D expense$1.79B$1.63B$1.54B$1.63B$1.48B$1.42B$1.33B$1.41B
SG&A expense$677.80M$662.10M$647.70M$775.00M$657.80M$634.20M$633.00M$792.20M
Operating income$2.05B$1.29B$642.90M$879.90M$1.03B$1.08B$591.70M$990.20M
Interest expense$10.60M$11.00M$12.90M$12.20M$19.30M$3.60M$8.70M$10.50M
Pretax income$2.28B$1.53B$831.20M$1.04B$1.76B$1.52B$905.00M$958.10M
Income tax$335.40M$230.90M$104.00M$199.10M$303.30M$127.10M$96.30M$40.40M
Net income$1.95B$1.30B$727.20M$844.60M$1.46B$1.39B$808.70M$917.70M
EBITDA$2.17B$1.42B$766.10M$1.02B$1.16B$1.21B$718.60M$1.12B
EPS (basic)19.1612.626.99—14.0913.247.58—
EPS (diluted)18.4512.236.75—13.6212.817.27—
Dividends declared per share0.940.940.940.880.880.880.88—
Weighted avg. shares (diluted)105.60M106.00M107.70M—107.20M108.60M111.20M—
Balance sheet
Cash & equivalents$3.66B$2.46B$2.96B$3.12B$2.51B$2.00B$3.09B$2.49B
Short-term investments$5.64B$5.54B$5.79B$5.49B$5.94B$5.47B$5.26B$6.52B
Receivables$7.58B$6.57B$5.73B$5.74B$5.69B$5.61B$5.56B$6.21B
Inventory$2.89B$3.08B$3.10B$3.20B$3.25B$3.21B$3.19B$3.09B
Current assets$20.80B$18.45B$18.21B$18.02B$17.98B$16.86B$17.57B$18.66B
PP&E, net$5.73B$5.46B$5.27B$5.12B$5.00B$4.84B$4.69B$4.60B
Intangibles$1.32B$1.31B$1.29B$1.26B$1.38B$1.35B$1.17B$1.15B
Total assets$44.41B$41.73B$40.87B$40.56B$40.17B$38.22B$37.55B$37.76B
Current liabilities$6.20B$5.53B$5.11B$4.37B$4.43B$3.67B$3.57B$3.94B
Long-term debt$1.99B$1.99B$1.99B$1.99B$1.99B$1.99B$1.98B$1.98B
Total debt$1.99B$1.99B$1.99B$1.99B$1.99B$1.99B$1.98B$1.98B
Total liabilities$10.91B$10.02B$9.45B$9.30B$9.21B$8.28B$8.16B$8.41B
Shareholders' equity$33.50B$31.71B$31.42B$31.26B$30.96B$29.94B$29.39B$29.35B
Net debt-$1.67B-$469.20M-$976.40M-$1.13B-$520.90M-$10.70M-$1.11B-$504.60M
Cash flow statement
Operating cash flow$1.78B$813.00M$1.08B$1.17B$1.62B$1.14B$1.05B$1.26B
Capital expenditure$300.20M$240.20M$230.60M$248.70M$201.40M$219.00M$229.30M$199.60M
Free cash flow$1.48B$572.80M$848.30M$922.00M$1.42B$925.40M$815.80M$1.06B
Investing cash flow-$288.10M-$92.70M-$428.90M$220.30M-$402.90M-$1.09B$647.50M$350.60M
Financing cash flow-$290.20M-$1.22B-$802.20M-$780.10M-$717.90M-$1.13B-$1.09B-$1.14B
Depreciation & amortization$121.00M$123.70M$123.20M$145.00M$136.70M$135.10M$126.90M$126.40M
Stock-based compensation$255.80M$243.00M$257.40M$249.30M$237.00M$251.70M$255.70M$304.40M
Dividends paid$95.70M$96.80M$97.80M$92.70M$91.20M$92.60M$93.80M$0
Share buybacks$399.70M$1.17B$794.30M$671.70M$664.00M$1.06B$1.04B$973.00M

Free plan shows the latest 8 periods; Pro shows all 70 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.